撰文丨王聪 编辑丨王多鱼 排版丨水成文 考虑到 癌症 的复杂性以及它所引发的免疫反应，癌症可以被视为一种全身性疾病。调动包括外周血、肿瘤引流淋巴结 （TDLN） 、脾脏和骨髓在内的全身免疫 反应，对于抑制癌症的发生和发展至关重要，这一机制在当前免疫治疗时代已被应用于肿瘤学实践。 然而，癌细胞会利用细胞内、细胞间以及器官间的活动来逃逸局部和全身免疫监视。然而，癌细胞如何利用远端组织和器官来逃逸全身免疫监视，在很大程度上 仍不清楚。 2025 年 10 月 24 日， 复旦大学附属中山医院 樊嘉 院士、 季彤 教授、 周俭 教授、 孙云帆 教授及上海交通大学医学院附属第九人民医院 张陈平 教授团队 合 作 （ 张誉 、 郭毅波 、 刘喆麒 、 孙仪庭 、 杨溪 为共同第一作者 ） ，在国际顶尖学术期刊 Cell 上发表了题为： Cancer cells co-opt an inter-organ neuroimmune circuit to escape immune surveillance 的研究论文。 该研究首次揭示，免疫压力下的肿瘤细胞可"劫持" 痛觉神经 以远程抑制 肿瘤引流淋巴结 （ TDLN ） 中 ...

Core Viewpoint - The article discusses the recent measures introduced by the National Healthcare Security Administration and the National Health Commission to support the high-quality development of innovative drugs in China, marking a significant shift from a generic drug powerhouse to an innovative drug leader since 2015 [1][2]. Group 1: Policy Measures and Support - The "Measures" introduced on July 1 aim to enhance the entire chain of support for innovative drug development, including research, payment, and access [1][2]. - Regions such as the Yangtze River Delta and the Pearl River Delta have allocated substantial financial resources to support drug innovation, providing concrete measures across various aspects of drug development [2][3]. Group 2: Current Landscape of Innovative Drugs - China currently has 1,775 first-in-class drug pipelines, accounting for 19% of the global total, and holds 14% of the global license-out transactions, with 30% of the total value [2]. - The article highlights the challenges faced in the drug development cycle, particularly the long timelines and high costs associated with innovative drug research [3]. Group 3: Clinical Institutions and Innovation - Clinical institutions play a crucial role in identifying unmet clinical needs, and there is a call for more involvement in source innovation to enhance the development of first-in-class drugs [4]. - The need for a unified data platform and an internationally recognized evaluation system is emphasized to facilitate clinical research and innovation [4]. Group 4: Real-World Data and Application - The "Guangdong-Hong Kong-Macao Drug and Device Pass" policy has enabled the introduction of innovative drugs and devices in pilot hospitals, benefiting over 6,000 patients and generating valuable real-world data [5]. - Real-world studies are essential for accelerating drug development and regulatory approval, as demonstrated by the successful completion of a study on a novel migraine treatment [5]. Group 5: Overcoming Barriers to Access - Efforts are being made to address the "last mile" challenges in getting innovative drugs into hospitals, including the establishment of a digital innovation laboratory to enhance data collection and evaluation [6]. - The article discusses the importance of risk assessment and safety evaluations for innovative drugs, particularly in oncology, to build confidence among healthcare providers [6]. - The overall goal is to create a win-win situation where patients have access to innovative treatments, funding is sustainable, and companies are motivated to innovate [6].

Core Viewpoint - Vitiligo is an autoimmune disease affecting approximately 0.5%-2% of the global population, characterized by white patches on the skin due to the attack of autoreactive CD8+ T cells on melanocytes. Recent research has identified a novel mechanism involving sensory neurons and CGRP that enhances CD8+ T cell responses, suggesting new therapeutic strategies for treatment [1][6][11]. Group 1: Disease Mechanism - The study reveals a new pathogenic mechanism in vitiligo involving a "sensory neuron-CGRP-cDC1-CD8 T cell" axis, where CGRP enhances the function of dermal type I conventional dendritic cells (cDC1) to drive autoreactive CD8 T cell responses [3][7][12]. - CD8+ T cells kill melanocytes in vitiligo, but the specific immune pathogenesis and ideal drug targets remain unclear [6]. Group 2: Therapeutic Development - Ruxolitinib cream, a selective JAK1/2 inhibitor, is the first approved treatment for non-segmental vitiligo, but it has a clinical response rate of about 30% and is associated with adverse events [1]. - The CGRP receptor antagonist Rimegepant has shown significant disease progression inhibition in mouse models and promising results in a clinical trial involving 57 vitiligo patients, indicating a new treatment strategy [3][8][11]. Group 3: Clinical Trial Insights - A clinical trial divided 57 vitiligo patients into three groups to assess the efficacy of Rimegepant cream combined with phototherapy, showing that the cream significantly improved skin repigmentation rates [8][11]. - The study utilized single-cell sequencing and spatial transcriptomics to analyze skin lesions, providing insights into the immune interactions involved in vitiligo [3][7].